[en] Today, there is increasing evidence that PPARgamma agonists, including thiazolidinediones (TDZs) and nonthiazolidinediones, block the motility and invasiveness of glioma cells and other highly migratory tumor entities. However, the mechanism(s) by which PPARgamma activators mediate their antimigratory and anti-invasive properties remains elusive. This letter gives a short review on the debate and adds to the current knowledge by applying a PPARgamma inactive derivative of the TDZ troglitazone (Rezulin) which potently counteracts experimental glioma progression in a PPARgamma independent manner.
Disciplines :
Neurology
Author, co-author :
Seufert, Sebastian; Institute of Human Genetics, Institute of Genetics, and Center for Molecular Medicine Cologne (CMMC), University of Cologne, Kerpener Street 34, 50931 Cologne, Germany
Coras, Roland; Institute of Neuropathology, University of Erlangen, Germany
Tränkle, Christian; Department of Pharmacology and Toxicology, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany
Zlotos, Darius P; Pharmaceutical Institute, University of Würzburg, 97074 Würzburg, Germany
Blümcke, Ingmar; Institute of Neuropathology, University of Erlangen, Germany
Tatenhorst, Lars; Department of Neurology, University of Bonn, 53105 Bonn, Germany
HENEKA, Michael ; Department of Neurology, University of Bonn, 53105 Bonn, Germany
Hahnen, Eric; Institute of Human Genetics, Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany
External co-authors :
yes
Language :
English
Title :
PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion.
DeAngelis L. M., Brain tumors New England Journal of Medicine 2001 344 2 114 123
Ohgaki H., Kleihues P., Epidemiology and etiology of gliomas Acta Neuropathologica 2005 109 1 93 108
Savaskan N. E., Heckel A., Hahnen E., Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema Nature Medicine 2008 14 6 629 632
Cobb J. E., Blanchard S. G., Boswell E. G., N -(2-benzoylphenyl)-L- tyrosine PPAR γ agonists. 3. Structure-activity relationship and optimization of the N -aryl substituent Journal of Medicinal Chemistry 1998 41 25 5055 5069
Grommes C., Landreth G. E., Schlegel U., Heneka M. T., The nonthiazolidinedione tyrosine-based peroxisome proliferator-activated receptor γ ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells Journal of Pharmacology and Experimental Therapeutics 2005 313 2 806 813
Grommes C., Landreth G. E., Sastre M., Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor γ agonist treatment Molecular Pharmacology 2006 70 5 1524 1533
Lakka S. S., Rajan M., Gondi C., Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion Oncogene 2002 21 52 8011 8019
Spagnolo A., Glick R. P., Lin H., Cohen E. P., Feinstein D. L., Lichtor T., Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor- γ thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts Journal of Neurosurgery 2007 106 2 299 305
Coras R., Hölsken A., Seufert S., The peroxisome proliferator-activated receptor- γ agonist troglitazone inhibits transforming growth factor- β -mediated glioma cell migration and brain invasion Molecular Cancer Therapeutics 2007 6 6 1745 1754
Eyüpoglu I. Y., Hahnen E., Heckel A., Malignant glioma-induced neuronal cell death in an organotypic glioma invasion model: technical note Journal of Neurosurgery 2005 102 4 738 744
Fan Y.-H., Chen H., Natarajan A., Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium Bioorganic and Medicinal Chemistry Letters 2004 14 10 2547 2550
Eyüpoglu I. Y., Hahnen E., Buslei R., Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo Journal of Neurochemistry 2005 93 4 992 999
Mosmann T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays Journal of Immunological Methods 1983 65 1-2 55 63
Liu H., Zang C., Fenner M. H., Possinger K., Elstner E., PPAR γ ligands and ATRA inhibit the invasion of human breast cancer cells in vitro Breast Cancer Research and Treatment 2003 79 1 63 74
Yang Y.-C., Ho T.-C., Chen S.-L., Lai H.-Y., Wu J.-W., Tsao Y.-P., Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line BMC Cancer 2007 7 1 216
van Nimwegen M. J., van de Water B., Focal adhesion kinase: a potential target in cancer therapy Biochemical Pharmacology 2007 73 5 597 609
Liu T.-J., LaFortune T., Honda T., Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo Molecular Cancer Therapeutics 2007 6 4 1357 1367
Demuth T., Berens M. E., Molecular mechanisms of glioma cell migration and invasion Journal of Neuro-Oncology 2004 70 2 217 228
Wick W., Platten M., Weller M., Glioma cell invasion: regulation of metalloproteinase activity by TGF- β Journal of Neuro-Oncology 2001 53 2 177 185
Merzak A., McCrea S., Koocheckpour S., Pilkington G. J., Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor β 1 British Journal of Cancer 1994 70 2 199 203
Platten M., Wick W., Wild-Bode C., Aulwurm S., Dichgans J., Weller M., Transforming growth factors β 1 (TGF- β 1) and TGF- β 2 promote glioma cell migration via up-regulation of α (v) β 3 integrin expression Biochemical and Biophysical Research Communications 2000 268 2 607 611
Wick W., Grimmel C., Wild-Bode C., Platten M., Arpin M., Weller M., Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor- β 2 The Journal of Neuroscience 2001 21 10 3360 3368
Uhl M., Aulwurm S., Wischhusen J., SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo Cancer Research 2004 64 21 7954 7961
Friese M. A., Wischhusen J., Wick W., RNA interference targeting transforming growth factor- β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo Cancer Research 2004 64 20 7596 7603
Hjelmeland M. D., Hjelmeland A. B., Sathornsumetee S., SB-431542, a small molecule transforming growth factor- β -receptor antagonist, inhibits human glioma cell line proliferation and motility Molecular Cancer Therapeutics 2004 3 6 737 745
Kjellman C., Olofsson S. P., Hansson O., Expression of TGF- β isoforms, TGF- β receptors, and Smad molecules at different stages of human glioma International Journal of Cancer 2000 89 3 251 258
Kawataki T., Naganuma H., Sasaki A., Yoshikawa H., Tasaka K., Nukui H., Correlation of thrombospondin-1 and transforming growth factor- β expression with malignancy of glioma Neuropathology 2000 20 3 161 169
Yamada N., Kato M., Yamashita H., Enhanced expression of transforming growth factor- β and its type-I and type-II receptors in human glioblastoma International Journal of Cancer 1995 62 4 386 392
Demuth T., Rennert J. L., Hoelzinger D. B., Glioma cells on the run-the migratory transcriptome of 10 human glioma cell lines BMC Genomics 2008 9, article 54
Eyüpoglu I. Y., Hahnen E., Tränkle C., Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275 Molecular Cancer Therapeutics 2006 5 5 1248 1255
Shiau C.-W., Yang C.-C., Kulp S. K., Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPAR γ Cancer Research 2005 65 4 1561 1569
Weng J.-R., Chen C.-Y., Pinzone J. J., Ringel M. D., Chen C.-S., Beyond peroxisome proliferator-activated receptor γ signaling: the multi-facets of the antitumor effect of thiazolidinediones Endocrine-Related Cancer 2006 13 2 401 413
Wick W., Naumann U., Weller M., Transforming growth factor- β: a molecular target for the future therapy of glioblastoma Current Pharmaceutical Design 2006 12 3 341 349
Hamel W., Westphal M., Growth factors in gliomas revisited Acta Neurochirurgica 2000 142 2 113 138
Gomez G. G., Kruse C. A., Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF- β Journal of Immunotherapy 2007 30 3 261 273
Ständer M., Naumann U., Dumitrescu L., Decorin gene transfer-mediated suppression of TGF- β synthesis abrogates experimental malignant glioma growth in vivo Gene Therapy 1998 5 9 1187 1194
Tran T.-T., Uhl M., Ma J. Y., Inhibiting TGF- β signaling restores immune surveillance in the SMA-560 glioma model Neuro-Oncology 2007 9 3 259 270
Loi C.-M., Young M., Randinitis E., Vassos A., Koup J. R., Clinical pharmacokinetics of troglitazone Clinical Pharmacokinetics 1999 37 2 91 104
Sampson J. H., Ashley D. M., Archer G. E., Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion Neurosurgery 1997 41 6 1365 1373
